Yi-chen Zhang

发表

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Clinical and translational medicine.

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2022, Journal of Cancer Research and Clinical Oncology.

Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC

Yi-long Wu, Yi-chen Zhang, Qing Zhou, 2016, Expert opinion on pharmacotherapy.

Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?

Chongrui Xu, Yi-chen Zhang, Qing Zhou, 2017, Expert review of molecular diagnostics.

Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives

Yi-chen Zhang, Zhi-hong Chen, Qing Zhou, 2022, Frontiers in Oncology.

A story of ALK variants and the efficacy of ALK inhibitors: moving toward precision oncology

Yi-long Wu, Yi-chen Zhang, H. Tu, 2017 .

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives.

Yi-long Wu, Yi-chen Zhang, Qing Zhou, 2019, Cancer letters.

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Ying Cheng, Yi-long Wu, B. Han, 2017, ESMO Open.

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

Yi-long Wu, Yi-chen Zhang, Qing Zhou, 2017, Journal of Hematology & Oncology.

Transsphenoidal resection of sellar tumors using high-field intraoperative magnetic resonance imaging.

M. Goldman, S. Karimi, V. Tabar, 2011, Skull base : official journal of North American Skull Base Society ... [et al.].

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third‐Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

Yi-long Wu, Jin-Ji Yang, Z. Wang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, EBioMedicine.

Heterogeneity in the immune microenvironment of bone metastasis in driver‐positive non‐small cell lung cancer

Weihua Luo, Xuchao Zhang, Dongqin Zhu, 2023, Molecular carcinogenesis.

Emerging challenges of advanced squamous cell lung cancer

Yi-long Wu, Yi-chen Zhang, Qing Zhou, 2016, ESMO Open.

The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge.

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, Science bulletin.

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

Jin-Ji Yang, W. Zhong, K. Yin, 2023, Molecular oncology.

Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2024, Oncoimmunology.

Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2024, Therapeutic advances in medical oncology.